nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclosporine—systemic lupus erythematosus—systemic scleroderma	0.211	0.365	CtDrD
Cyclosporine—rheumatoid arthritis—systemic scleroderma	0.199	0.345	CtDrD
Cyclosporine—psoriasis—systemic scleroderma	0.167	0.289	CtDrD
Cyclosporine—ABCG2—Leflunomide—systemic scleroderma	0.0218	0.0876	CbGbCtD
Cyclosporine—ABCC10—Methotrexate—systemic scleroderma	0.0209	0.084	CbGbCtD
Cyclosporine—CYP2C8—Mometasone—systemic scleroderma	0.0181	0.0724	CbGbCtD
Cyclosporine—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.017	0.0681	CbGbCtD
Cyclosporine—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0149	0.0599	CbGbCtD
Cyclosporine—SLCO1A2—Prednisone—systemic scleroderma	0.0144	0.0577	CbGbCtD
Cyclosporine—SLC22A6—Captopril—systemic scleroderma	0.0139	0.0556	CbGbCtD
Cyclosporine—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0135	0.0541	CbGbCtD
Cyclosporine—ABCC3—Methotrexate—systemic scleroderma	0.0132	0.0528	CbGbCtD
Cyclosporine—ABCB1—Lisinopril—systemic scleroderma	0.00825	0.0331	CbGbCtD
Cyclosporine—CYP2C9—Leflunomide—systemic scleroderma	0.00811	0.0325	CbGbCtD
Cyclosporine—ABCC1—Methotrexate—systemic scleroderma	0.00808	0.0324	CbGbCtD
Cyclosporine—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.00747	0.03	CbGbCtD
Cyclosporine—SLCO1A2—Methotrexate—systemic scleroderma	0.00722	0.029	CbGbCtD
Cyclosporine—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.00719	0.0288	CbGbCtD
Cyclosporine—SLCO1B1—Methotrexate—systemic scleroderma	0.00681	0.0273	CbGbCtD
Cyclosporine—ABCB1—Captopril—systemic scleroderma	0.00618	0.0248	CbGbCtD
Cyclosporine—ABCC2—Methotrexate—systemic scleroderma	0.00598	0.024	CbGbCtD
Cyclosporine—CYP2D6—Captopril—systemic scleroderma	0.00582	0.0234	CbGbCtD
Cyclosporine—ABCG2—Methotrexate—systemic scleroderma	0.00541	0.0217	CbGbCtD
Cyclosporine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00486	0.0195	CbGbCtD
Cyclosporine—CYP2C19—Prednisone—systemic scleroderma	0.00482	0.0193	CbGbCtD
Cyclosporine—SLC22A6—Methotrexate—systemic scleroderma	0.00438	0.0176	CbGbCtD
Cyclosporine—ABCB1—Prednisone—systemic scleroderma	0.00389	0.0156	CbGbCtD
Cyclosporine—CYP2C9—cardial valve—systemic scleroderma	0.00323	0.111	CbGeAlD
Cyclosporine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00291	0.0117	CbGbCtD
Cyclosporine—CYP3A4—Prednisone—systemic scleroderma	0.00233	0.00935	CbGbCtD
Cyclosporine—ABCB1—Methotrexate—systemic scleroderma	0.00195	0.00783	CbGbCtD
Cyclosporine—PPID—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00155	0.055	CbGpPWpGaD
Cyclosporine—PPIB—Syndecan-1-mediated signaling events—COL1A2—systemic scleroderma	0.00127	0.0452	CbGpPWpGaD
Cyclosporine—FKBP4—connective tissue—systemic scleroderma	0.00106	0.0362	CbGeAlD
Cyclosporine—FKBP1B—lung—systemic scleroderma	0.000964	0.033	CbGeAlD
Cyclosporine—FKBP4—skin of body—systemic scleroderma	0.000954	0.0327	CbGeAlD
Cyclosporine—PPID—smooth muscle tissue—systemic scleroderma	0.000892	0.0306	CbGeAlD
Cyclosporine—PPIB—Collagen biosynthesis and modifying enzymes—COL1A2—systemic scleroderma	0.00086	0.0305	CbGpPWpGaD
Cyclosporine—FKBP1A—ALK1 signaling events—SMAD7—systemic scleroderma	0.000854	0.0303	CbGpPWpGaD
Cyclosporine—SLC10A2—digestive system—systemic scleroderma	0.00077	0.0264	CbGeAlD
Cyclosporine—FKBP4—digestive system—systemic scleroderma	0.000763	0.0262	CbGeAlD
Cyclosporine—FKBP4—tendon—systemic scleroderma	0.000727	0.0249	CbGeAlD
Cyclosporine—FKBP1A—TGF-beta receptor signaling activates SMADs—SMAD7—systemic scleroderma	0.000723	0.0257	CbGpPWpGaD
Cyclosporine—FKBP4—Androgen receptor signaling pathway—RHOB—systemic scleroderma	0.00072	0.0256	CbGpPWpGaD
Cyclosporine—FKBP1B—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00071	0.0252	CbGpPWpGaD
Cyclosporine—PPP3CA—connective tissue—systemic scleroderma	0.000679	0.0233	CbGeAlD
Cyclosporine—PPIB—connective tissue—systemic scleroderma	0.000675	0.0231	CbGeAlD
Cyclosporine—PPIB—Collagen formation—COL1A2—systemic scleroderma	0.000675	0.024	CbGpPWpGaD
Cyclosporine—PPID—tendon—systemic scleroderma	0.00067	0.023	CbGeAlD
Cyclosporine—CAMLG—tendon—systemic scleroderma	0.000661	0.0227	CbGeAlD
Cyclosporine—PPIF—smooth muscle tissue—systemic scleroderma	0.000649	0.0222	CbGeAlD
Cyclosporine—PPIF—skin of body—systemic scleroderma	0.00064	0.0219	CbGeAlD
Cyclosporine—FKBP4—lung—systemic scleroderma	0.000638	0.0219	CbGeAlD
Cyclosporine—PPP3CA—Spinal Cord Injury—AIF1—systemic scleroderma	0.000625	0.0222	CbGpPWpGaD
Cyclosporine—PPP3CA—smooth muscle tissue—systemic scleroderma	0.000621	0.0213	CbGeAlD
Cyclosporine—FKBP4—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.000621	0.022	CbGpPWpGaD
Cyclosporine—PPIB—smooth muscle tissue—systemic scleroderma	0.000618	0.0212	CbGeAlD
Cyclosporine—PPIB—skin of body—systemic scleroderma	0.00061	0.0209	CbGeAlD
Cyclosporine—PPIA—tendon—systemic scleroderma	0.000602	0.0206	CbGeAlD
Cyclosporine—PPID—lung—systemic scleroderma	0.000588	0.0202	CbGeAlD
Cyclosporine—CAMLG—lung—systemic scleroderma	0.00058	0.0199	CbGeAlD
Cyclosporine—PPIB—Syndecan-1-mediated signaling events—MMP1—systemic scleroderma	0.000579	0.0206	CbGpPWpGaD
Cyclosporine—PPIA—lung—systemic scleroderma	0.000528	0.0181	CbGeAlD
Cyclosporine—PPIF—digestive system—systemic scleroderma	0.000512	0.0176	CbGeAlD
Cyclosporine—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—CTLA4—systemic scleroderma	0.000506	0.018	CbGpPWpGaD
Cyclosporine—PPP3CA—digestive system—systemic scleroderma	0.00049	0.0168	CbGeAlD
Cyclosporine—FKBP1A—TGF-beta receptor signaling—SMAD7—systemic scleroderma	0.00049	0.0174	CbGpPWpGaD
Cyclosporine—PPIB—digestive system—systemic scleroderma	0.000488	0.0167	CbGeAlD
Cyclosporine—PPIF—tendon—systemic scleroderma	0.000488	0.0167	CbGeAlD
Cyclosporine—FKBP1A—Spinal Cord Injury—AIF1—systemic scleroderma	0.000484	0.0172	CbGpPWpGaD
Cyclosporine—FKBP1A—TGF-beta Receptor Signaling—SMAD7—systemic scleroderma	0.000476	0.0169	CbGpPWpGaD
Cyclosporine—PPP3CA—tendon—systemic scleroderma	0.000467	0.016	CbGeAlD
Cyclosporine—PPIB—tendon—systemic scleroderma	0.000464	0.0159	CbGeAlD
Cyclosporine—FKBP1A—Alpha-synuclein signaling—BLK—systemic scleroderma	0.000454	0.0161	CbGpPWpGaD
Cyclosporine—PPIA—Basigin interactions—MMP1—systemic scleroderma	0.000454	0.0161	CbGpPWpGaD
Cyclosporine—FKBP1A—connective tissue—systemic scleroderma	0.000451	0.0155	CbGeAlD
Cyclosporine—PPP3CA—Physiological and Pathological Hypertrophy  of the Heart—EDN1—systemic scleroderma	0.000449	0.0159	CbGpPWpGaD
Cyclosporine—PPIA—Platelet degranulation—SELP—systemic scleroderma	0.000447	0.0159	CbGpPWpGaD
Cyclosporine—PPIF—lung—systemic scleroderma	0.000428	0.0147	CbGeAlD
Cyclosporine—PPIA—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000425	0.0151	CbGpPWpGaD
Cyclosporine—SLC10A1—digestive system—systemic scleroderma	0.000417	0.0143	CbGeAlD
Cyclosporine—FKBP1A—smooth muscle tissue—systemic scleroderma	0.000413	0.0141	CbGeAlD
Cyclosporine—ABCB11—digestive system—systemic scleroderma	0.000412	0.0141	CbGeAlD
Cyclosporine—PPP3CA—lung—systemic scleroderma	0.00041	0.014	CbGeAlD
Cyclosporine—FKBP1A—skin of body—systemic scleroderma	0.000407	0.014	CbGeAlD
Cyclosporine—PPIB—lung—systemic scleroderma	0.000407	0.014	CbGeAlD
Cyclosporine—FKBP1A—Loss of Function of SMAD2/3 in Cancer—SMAD7—systemic scleroderma	0.000386	0.0137	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—FBN1—systemic scleroderma	0.000386	0.0137	CbGpPWpGaD
Cyclosporine—PPIA—Cell surface interactions at the vascular wall—SELP—systemic scleroderma	0.000377	0.0134	CbGpPWpGaD
Cyclosporine—PPP3CA—BCR signaling pathway—CSK—systemic scleroderma	0.000364	0.0129	CbGpPWpGaD
Cyclosporine—PPIB—Syndecan-1-mediated signaling events—MMP9—systemic scleroderma	0.000337	0.012	CbGpPWpGaD
Cyclosporine—FKBP4—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.00033	0.0117	CbGpPWpGaD
Cyclosporine—FKBP1A—digestive system—systemic scleroderma	0.000326	0.0112	CbGeAlD
Cyclosporine—PPP3CA—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000314	0.0112	CbGpPWpGaD
Cyclosporine—FKBP1A—tendon—systemic scleroderma	0.00031	0.0106	CbGeAlD
Cyclosporine—PPP3R2—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000309	0.011	CbGpPWpGaD
Cyclosporine—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.000305	0.0108	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000305	0.0108	CbGpPWpGaD
Cyclosporine—PPIA—Cell surface interactions at the vascular wall—ITGAM—systemic scleroderma	0.000301	0.0107	CbGpPWpGaD
Cyclosporine—PPP3R2—Alzheimers Disease—IL1B—systemic scleroderma	0.000294	0.0105	CbGpPWpGaD
Cyclosporine—PPIB—Syndecan-1-mediated signaling events—TGFB1—systemic scleroderma	0.000278	0.00985	CbGpPWpGaD
Cyclosporine—SLCO1B1—digestive system—systemic scleroderma	0.000276	0.00948	CbGeAlD
Cyclosporine—FKBP1A—lung—systemic scleroderma	0.000272	0.00933	CbGeAlD
Cyclosporine—PPP3CA—Spinal Cord Injury—SELP—systemic scleroderma	0.000272	0.00966	CbGpPWpGaD
Cyclosporine—FKBP1A—TGF-beta receptor signaling—CTGF—systemic scleroderma	0.000271	0.00962	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—COL1A2—systemic scleroderma	0.00027	0.00958	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—HSPG2—systemic scleroderma	0.00027	0.00958	CbGpPWpGaD
Cyclosporine—ABCC3—digestive system—systemic scleroderma	0.000262	0.00899	CbGeAlD
Cyclosporine—ABCC10—digestive system—systemic scleroderma	0.000261	0.00895	CbGeAlD
Cyclosporine—PPP3CA—Spinal Cord Injury—RHOB—systemic scleroderma	0.000254	0.00902	CbGpPWpGaD
Cyclosporine—ABCC10—tendon—systemic scleroderma	0.000248	0.00852	CbGeAlD
Cyclosporine—PPIA—Host Interactions of HIV factors—CD247—systemic scleroderma	0.000248	0.00881	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000245	0.0087	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000237	0.0084	CbGpPWpGaD
Cyclosporine—SLCO1A2—digestive system—systemic scleroderma	0.000225	0.00771	CbGeAlD
Cyclosporine—ABCC3—lung—systemic scleroderma	0.000219	0.00751	CbGeAlD
Cyclosporine—ABCC10—lung—systemic scleroderma	0.000218	0.00747	CbGeAlD
Cyclosporine—FKBP1A—Spinal Cord Injury—SELP—systemic scleroderma	0.000211	0.00749	CbGpPWpGaD
Cyclosporine—ABCC2—digestive system—systemic scleroderma	0.00021	0.00718	CbGeAlD
Cyclosporine—ABCB1—blood vessel—systemic scleroderma	0.000204	0.00698	CbGeAlD
Cyclosporine—FKBP1A—TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)—TGFB1—systemic scleroderma	0.0002	0.00711	CbGpPWpGaD
Cyclosporine—ABCC2—tendon—systemic scleroderma	0.000199	0.00684	CbGeAlD
Cyclosporine—PPIA—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000198	0.00703	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—RHOB—systemic scleroderma	0.000197	0.00699	CbGpPWpGaD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000194	0.0069	CbGpPWpGaD
Cyclosporine—SLCO1A2—lung—systemic scleroderma	0.000188	0.00644	CbGeAlD
Cyclosporine—PPIA—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000185	0.00657	CbGpPWpGaD
Cyclosporine—CYP2C19—digestive system—systemic scleroderma	0.00018	0.00617	CbGeAlD
Cyclosporine—PPIB—Collagen formation—MMP9—systemic scleroderma	0.000179	0.00634	CbGpPWpGaD
Cyclosporine—ABCC1—tendon—systemic scleroderma	0.000176	0.00602	CbGeAlD
Cyclosporine—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00017	0.00604	CbGpPWpGaD
Cyclosporine—PPIA—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000168	0.00598	CbGpPWpGaD
Cyclosporine—PPIA—HIV Infection—CD247—systemic scleroderma	0.000161	0.00573	CbGpPWpGaD
Cyclosporine—PPP3R2—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000161	0.00572	CbGpPWpGaD
Cyclosporine—ABCC1—lung—systemic scleroderma	0.000154	0.00529	CbGeAlD
Cyclosporine—FKBP4—Cellular responses to stress—IL1A—systemic scleroderma	0.000153	0.00544	CbGpPWpGaD
Cyclosporine—PPIA—Cell surface interactions at the vascular wall—MMP1—systemic scleroderma	0.000151	0.00536	CbGpPWpGaD
Cyclosporine—CYP3A5—digestive system—systemic scleroderma	0.000142	0.00486	CbGeAlD
Cyclosporine—CYP2C9—digestive system—systemic scleroderma	0.00014	0.00479	CbGeAlD
Cyclosporine—FKBP1A—ALK1 signaling events—TGFB1—systemic scleroderma	0.000136	0.00482	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—IL1A—systemic scleroderma	0.000129	0.00458	CbGpPWpGaD
Cyclosporine—ABCG2—lung—systemic scleroderma	0.000128	0.00438	CbGeAlD
Cyclosporine—PPP3R2—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000125	0.00444	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—MMP1—systemic scleroderma	0.000123	0.00436	CbGpPWpGaD
Cyclosporine—CYP3A5—lung—systemic scleroderma	0.000119	0.00406	CbGeAlD
Cyclosporine—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFB1—systemic scleroderma	0.000115	0.00408	CbGpPWpGaD
Cyclosporine—CYP3A4—digestive system—systemic scleroderma	0.000106	0.00365	CbGeAlD
Cyclosporine—CYP2D6—digestive system—systemic scleroderma	0.000105	0.00359	CbGeAlD
Cyclosporine—PPIA—Hemostasis—SELP—systemic scleroderma	0.000102	0.00363	CbGpPWpGaD
Cyclosporine—FKBP1B—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000101	0.00357	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—IL1A—systemic scleroderma	9.99e-05	0.00355	CbGpPWpGaD
Cyclosporine—PPP3CA—MAPK Signaling Pathway—IL1A—systemic scleroderma	9.72e-05	0.00345	CbGpPWpGaD
Cyclosporine—PPP3CA—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	9.62e-05	0.00342	CbGpPWpGaD
Cyclosporine—PPIA—Hemostasis—RHOB—systemic scleroderma	9.53e-05	0.00338	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—MMP2—systemic scleroderma	9.5e-05	0.00337	CbGpPWpGaD
Cyclosporine—SLC10A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	9.41e-05	0.00334	CbGpPWpGaD
Cyclosporine—PPP3CA—Alzheimers Disease—IL1B—systemic scleroderma	9.27e-05	0.00329	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—CCL2—systemic scleroderma	8.86e-05	0.00315	CbGpPWpGaD
Cyclosporine—PPIA—Hemostasis—CSK—systemic scleroderma	8.68e-05	0.00308	CbGpPWpGaD
Cyclosporine—PPIA—Platelet degranulation—TGFB1—systemic scleroderma	8.58e-05	0.00305	CbGpPWpGaD
Cyclosporine—PPIA—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	8.17e-05	0.0029	CbGpPWpGaD
Cyclosporine—PPIA—Hemostasis—ITGAM—systemic scleroderma	8.16e-05	0.0029	CbGpPWpGaD
Cyclosporine—FKBP1A—TGF-beta receptor signaling—TGFB1—systemic scleroderma	7.8e-05	0.00277	CbGpPWpGaD
Cyclosporine—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	7.66e-05	0.00272	CbGpPWpGaD
Cyclosporine—FKBP1A—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	7.57e-05	0.00269	CbGpPWpGaD
Cyclosporine—ABCB1—digestive system—systemic scleroderma	7.54e-05	0.00258	CbGeAlD
Cyclosporine—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	7.17e-05	0.00254	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—MMP9—systemic scleroderma	7.14e-05	0.00254	CbGpPWpGaD
Cyclosporine—SLC10A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.13e-05	0.00253	CbGpPWpGaD
Cyclosporine—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	7.05e-05	0.0025	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—CCL2—systemic scleroderma	6.87e-05	0.00244	CbGpPWpGaD
Cyclosporine—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	6.85e-05	0.00243	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—IL1B—systemic scleroderma	6.72e-05	0.00239	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—MMP9—systemic scleroderma	6.34e-05	0.00225	CbGpPWpGaD
Cyclosporine—ABCB1—lung—systemic scleroderma	6.3e-05	0.00216	CbGeAlD
Cyclosporine—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFB1—systemic scleroderma	6.15e-05	0.00218	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—ITGAM—systemic scleroderma	6.11e-05	0.00217	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—CD247—systemic scleroderma	6.11e-05	0.00217	CbGpPWpGaD
Cyclosporine—SLC10A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.06e-05	0.00215	CbGpPWpGaD
Cyclosporine—PPIA—Disease—SMAD7—systemic scleroderma	5.97e-05	0.00212	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—TGFB1—systemic scleroderma	5.89e-05	0.00209	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—TNFAIP3—systemic scleroderma	5.72e-05	0.00203	CbGpPWpGaD
Cyclosporine—PPIA—Disease—TGFBI—systemic scleroderma	5.46e-05	0.00194	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—IL13—systemic scleroderma	5.3e-05	0.00188	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—TGFB1—systemic scleroderma	5.22e-05	0.00185	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—IL1B—systemic scleroderma	5.21e-05	0.00185	CbGpPWpGaD
Cyclosporine—PPP3CA—MAPK Signaling Pathway—IL1B—systemic scleroderma	5.07e-05	0.0018	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—SMAD7—systemic scleroderma	4.96e-05	0.00176	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—MMP9—systemic scleroderma	4.91e-05	0.00174	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	4.7e-05	0.00167	CbGpPWpGaD
Cyclosporine—SLC10A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.59e-05	0.00163	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling by GPCR—RHOB—systemic scleroderma	4.55e-05	0.00161	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—TGFBI—systemic scleroderma	4.53e-05	0.00161	CbGpPWpGaD
Cyclosporine—PPIA—Disease—HSPG2—systemic scleroderma	4.35e-05	0.00155	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	4.26e-05	0.00151	CbGpPWpGaD
Cyclosporine—PPIA—Disease—CSK—systemic scleroderma	4.2e-05	0.00149	CbGpPWpGaD
Cyclosporine—SLC10A2—Metabolism—HSPG2—systemic scleroderma	4.19e-05	0.00149	CbGpPWpGaD
Cyclosporine—PPIA—Hemostasis—MMP1—systemic scleroderma	4.09e-05	0.00145	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—TGFB1—systemic scleroderma	4.05e-05	0.00144	CbGpPWpGaD
Cyclosporine—PPIA—Disease—CD247—systemic scleroderma	3.95e-05	0.0014	CbGpPWpGaD
Cyclosporine—PPP3CA—MAPK Signaling Pathway—TGFB1—systemic scleroderma	3.94e-05	0.0014	CbGpPWpGaD
Cyclosporine—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	3.87e-05	0.00138	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—SMAD7—systemic scleroderma	3.84e-05	0.00137	CbGpPWpGaD
Cyclosporine—Nausea—Mometasone—systemic scleroderma	3.83e-05	0.000331	CcSEcCtD
Cyclosporine—Anorexia—Lisinopril—systemic scleroderma	3.83e-05	0.000331	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Leflunomide—systemic scleroderma	3.82e-05	0.00033	CcSEcCtD
Cyclosporine—Weight increased—Prednisone—systemic scleroderma	3.82e-05	0.00033	CcSEcCtD
Cyclosporine—Constipation—Mycophenolic acid—systemic scleroderma	3.81e-05	0.000329	CcSEcCtD
Cyclosporine—Pain—Mycophenolic acid—systemic scleroderma	3.81e-05	0.000329	CcSEcCtD
Cyclosporine—PPIA—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.8e-05	0.00135	CbGpPWpGaD
Cyclosporine—Weight decreased—Prednisone—systemic scleroderma	3.79e-05	0.000328	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—CSK—systemic scleroderma	3.78e-05	0.00134	CbGpPWpGaD
Cyclosporine—Hyperglycaemia—Prednisone—systemic scleroderma	3.78e-05	0.000327	CcSEcCtD
Cyclosporine—Cough—Mycophenolate mofetil—systemic scleroderma	3.76e-05	0.000325	CcSEcCtD
Cyclosporine—Dizziness—Captopril—systemic scleroderma	3.75e-05	0.000324	CcSEcCtD
Cyclosporine—Convulsion—Mycophenolate mofetil—systemic scleroderma	3.73e-05	0.000323	CcSEcCtD
Cyclosporine—Depression—Prednisone—systemic scleroderma	3.73e-05	0.000322	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—IRF5—systemic scleroderma	3.72e-05	0.00132	CbGpPWpGaD
Cyclosporine—Hypertension—Mycophenolate mofetil—systemic scleroderma	3.72e-05	0.000322	CcSEcCtD
Cyclosporine—Urticaria—Leflunomide—systemic scleroderma	3.71e-05	0.000321	CcSEcCtD
Cyclosporine—Abdominal pain—Leflunomide—systemic scleroderma	3.69e-05	0.000319	CcSEcCtD
Cyclosporine—Body temperature increased—Leflunomide—systemic scleroderma	3.69e-05	0.000319	CcSEcCtD
Cyclosporine—Acute coronary syndrome—Prednisone—systemic scleroderma	3.68e-05	0.000319	CcSEcCtD
Cyclosporine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	3.67e-05	0.000317	CcSEcCtD
Cyclosporine—Chest pain—Mycophenolate mofetil—systemic scleroderma	3.67e-05	0.000317	CcSEcCtD
Cyclosporine—Myalgia—Mycophenolate mofetil—systemic scleroderma	3.67e-05	0.000317	CcSEcCtD
Cyclosporine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	3.67e-05	0.000317	CcSEcCtD
Cyclosporine—Myocardial infarction—Prednisone—systemic scleroderma	3.66e-05	0.000317	CcSEcCtD
Cyclosporine—Neuropathy peripheral—Prednisone—systemic scleroderma	3.66e-05	0.000317	CcSEcCtD
Cyclosporine—Breast disorder—Methotrexate—systemic scleroderma	3.66e-05	0.000317	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	3.66e-05	0.000316	CcSEcCtD
Cyclosporine—Anxiety—Mycophenolate mofetil—systemic scleroderma	3.66e-05	0.000316	CcSEcCtD
Cyclosporine—Hypersensitivity—Azathioprine—systemic scleroderma	3.64e-05	0.000315	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	3.64e-05	0.000315	CcSEcCtD
Cyclosporine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	3.64e-05	0.000315	CcSEcCtD
Cyclosporine—Insomnia—Lisinopril—systemic scleroderma	3.63e-05	0.000314	CcSEcCtD
Cyclosporine—Discomfort—Mycophenolate mofetil—systemic scleroderma	3.62e-05	0.000313	CcSEcCtD
Cyclosporine—PPP3CA—Disease—HSPG2—systemic scleroderma	3.62e-05	0.00128	CbGpPWpGaD
Cyclosporine—Paraesthesia—Lisinopril—systemic scleroderma	3.6e-05	0.000312	CcSEcCtD
Cyclosporine—Vomiting—Captopril—systemic scleroderma	3.6e-05	0.000312	CcSEcCtD
Cyclosporine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	3.59e-05	0.00031	CcSEcCtD
Cyclosporine—Dyspnoea—Lisinopril—systemic scleroderma	3.58e-05	0.000309	CcSEcCtD
Cyclosporine—Rash—Captopril—systemic scleroderma	3.57e-05	0.000309	CcSEcCtD
Cyclosporine—ABCB11—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.57e-05	0.00127	CbGpPWpGaD
Cyclosporine—Dermatitis—Captopril—systemic scleroderma	3.57e-05	0.000309	CcSEcCtD
Cyclosporine—Somnolence—Lisinopril—systemic scleroderma	3.57e-05	0.000309	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—ITGAM—systemic scleroderma	3.56e-05	0.00126	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—IRF8—systemic scleroderma	3.56e-05	0.00126	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—CD247—systemic scleroderma	3.56e-05	0.00126	CbGpPWpGaD
Cyclosporine—Headache—Captopril—systemic scleroderma	3.55e-05	0.000307	CcSEcCtD
Cyclosporine—Confusional state—Mycophenolate mofetil—systemic scleroderma	3.55e-05	0.000307	CcSEcCtD
Cyclosporine—Dyspepsia—Lisinopril—systemic scleroderma	3.53e-05	0.000305	CcSEcCtD
Cyclosporine—Body temperature increased—Mycophenolic acid—systemic scleroderma	3.52e-05	0.000305	CcSEcCtD
Cyclosporine—Abdominal pain—Mycophenolic acid—systemic scleroderma	3.52e-05	0.000305	CcSEcCtD
Cyclosporine—Oedema—Mycophenolate mofetil—systemic scleroderma	3.52e-05	0.000304	CcSEcCtD
Cyclosporine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	3.52e-05	0.000304	CcSEcCtD
Cyclosporine—FKBP1A—Disease—TGFBI—systemic scleroderma	3.52e-05	0.00125	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	3.51e-05	0.00125	CbGpPWpGaD
Cyclosporine—Infection—Mycophenolate mofetil—systemic scleroderma	3.49e-05	0.000302	CcSEcCtD
Cyclosporine—PPP3CA—Disease—CSK—systemic scleroderma	3.49e-05	0.00124	CbGpPWpGaD
Cyclosporine—Decreased appetite—Lisinopril—systemic scleroderma	3.49e-05	0.000302	CcSEcCtD
Cyclosporine—PPP3CA—Signaling Pathways—SMAD7—systemic scleroderma	3.47e-05	0.00123	CbGpPWpGaD
Cyclosporine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	3.47e-05	0.0003	CcSEcCtD
Cyclosporine—Fatigue—Lisinopril—systemic scleroderma	3.46e-05	0.000299	CcSEcCtD
Cyclosporine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	3.45e-05	0.000298	CcSEcCtD
Cyclosporine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	3.44e-05	0.000298	CcSEcCtD
Cyclosporine—Hypersensitivity—Leflunomide—systemic scleroderma	3.44e-05	0.000298	CcSEcCtD
Cyclosporine—Pancreatitis—Methotrexate—systemic scleroderma	3.44e-05	0.000297	CcSEcCtD
Cyclosporine—Pain—Lisinopril—systemic scleroderma	3.43e-05	0.000297	CcSEcCtD
Cyclosporine—Constipation—Lisinopril—systemic scleroderma	3.43e-05	0.000297	CcSEcCtD
Cyclosporine—ABCC3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.43e-05	0.00122	CbGpPWpGaD
Cyclosporine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	3.42e-05	0.000295	CcSEcCtD
Cyclosporine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	3.4e-05	0.000294	CcSEcCtD
Cyclosporine—Diarrhoea—Azathioprine—systemic scleroderma	3.38e-05	0.000293	CcSEcCtD
Cyclosporine—Haemoglobin—Prednisone—systemic scleroderma	3.37e-05	0.000292	CcSEcCtD
Cyclosporine—Nausea—Captopril—systemic scleroderma	3.37e-05	0.000291	CcSEcCtD
Cyclosporine—Abdominal discomfort—Methotrexate—systemic scleroderma	3.36e-05	0.00029	CcSEcCtD
Cyclosporine—Haemorrhage—Prednisone—systemic scleroderma	3.36e-05	0.00029	CcSEcCtD
Cyclosporine—Anorexia—Mycophenolate mofetil—systemic scleroderma	3.35e-05	0.00029	CcSEcCtD
Cyclosporine—Asthenia—Leflunomide—systemic scleroderma	3.35e-05	0.00029	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	3.34e-05	0.00118	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—TNFAIP3—systemic scleroderma	3.33e-05	0.00118	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	3.32e-05	0.00118	CbGpPWpGaD
Cyclosporine—Feeling abnormal—Lisinopril—systemic scleroderma	3.31e-05	0.000286	CcSEcCtD
Cyclosporine—Pruritus—Leflunomide—systemic scleroderma	3.31e-05	0.000286	CcSEcCtD
Cyclosporine—Connective tissue disorder—Prednisone—systemic scleroderma	3.3e-05	0.000285	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—BLK—systemic scleroderma	3.29e-05	0.00117	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—CD247—systemic scleroderma	3.28e-05	0.00117	CbGpPWpGaD
Cyclosporine—Gastrointestinal pain—Lisinopril—systemic scleroderma	3.28e-05	0.000284	CcSEcCtD
Cyclosporine—Dysuria—Methotrexate—systemic scleroderma	3.28e-05	0.000283	CcSEcCtD
Cyclosporine—Dizziness—Azathioprine—systemic scleroderma	3.27e-05	0.000283	CcSEcCtD
Cyclosporine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	3.26e-05	0.000282	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	3.2e-05	0.000277	CcSEcCtD
Cyclosporine—Asthenia—Mycophenolic acid—systemic scleroderma	3.2e-05	0.000276	CcSEcCtD
Cyclosporine—Diarrhoea—Leflunomide—systemic scleroderma	3.2e-05	0.000276	CcSEcCtD
Cyclosporine—Urticaria—Lisinopril—systemic scleroderma	3.19e-05	0.000276	CcSEcCtD
Cyclosporine—Insomnia—Mycophenolate mofetil—systemic scleroderma	3.18e-05	0.000275	CcSEcCtD
Cyclosporine—SLC10A2—Metabolism—CTGF—systemic scleroderma	3.18e-05	0.00113	CbGpPWpGaD
Cyclosporine—Abdominal pain—Lisinopril—systemic scleroderma	3.17e-05	0.000274	CcSEcCtD
Cyclosporine—Body temperature increased—Lisinopril—systemic scleroderma	3.17e-05	0.000274	CcSEcCtD
Cyclosporine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	3.16e-05	0.000273	CcSEcCtD
Cyclosporine—Pruritus—Mycophenolic acid—systemic scleroderma	3.15e-05	0.000273	CcSEcCtD
Cyclosporine—Vomiting—Azathioprine—systemic scleroderma	3.15e-05	0.000272	CcSEcCtD
Cyclosporine—Pneumonia—Methotrexate—systemic scleroderma	3.14e-05	0.000272	CcSEcCtD
Cyclosporine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	3.14e-05	0.000271	CcSEcCtD
Cyclosporine—Somnolence—Mycophenolate mofetil—systemic scleroderma	3.13e-05	0.00027	CcSEcCtD
Cyclosporine—Infestation NOS—Methotrexate—systemic scleroderma	3.12e-05	0.00027	CcSEcCtD
Cyclosporine—Infestation—Methotrexate—systemic scleroderma	3.12e-05	0.00027	CcSEcCtD
Cyclosporine—Rash—Azathioprine—systemic scleroderma	3.12e-05	0.00027	CcSEcCtD
Cyclosporine—Dermatitis—Azathioprine—systemic scleroderma	3.12e-05	0.000269	CcSEcCtD
Cyclosporine—Depression—Methotrexate—systemic scleroderma	3.11e-05	0.000269	CcSEcCtD
Cyclosporine—Flushing—Prednisone—systemic scleroderma	3.11e-05	0.000269	CcSEcCtD
Cyclosporine—Headache—Azathioprine—systemic scleroderma	3.1e-05	0.000268	CcSEcCtD
Cyclosporine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	3.1e-05	0.000268	CcSEcCtD
Cyclosporine—Dizziness—Leflunomide—systemic scleroderma	3.09e-05	0.000267	CcSEcCtD
Cyclosporine—Renal failure—Methotrexate—systemic scleroderma	3.07e-05	0.000265	CcSEcCtD
Cyclosporine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	3.06e-05	0.000264	CcSEcCtD
Cyclosporine—Diarrhoea—Mycophenolic acid—systemic scleroderma	3.05e-05	0.000264	CcSEcCtD
Cyclosporine—Stomatitis—Methotrexate—systemic scleroderma	3.05e-05	0.000263	CcSEcCtD
Cyclosporine—Angiopathy—Prednisone—systemic scleroderma	3.04e-05	0.000263	CcSEcCtD
Cyclosporine—Conjunctivitis—Methotrexate—systemic scleroderma	3.04e-05	0.000263	CcSEcCtD
Cyclosporine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	3.04e-05	0.000262	CcSEcCtD
Cyclosporine—Pain—Mycophenolate mofetil—systemic scleroderma	3.01e-05	0.00026	CcSEcCtD
Cyclosporine—Constipation—Mycophenolate mofetil—systemic scleroderma	3.01e-05	0.00026	CcSEcCtD
Cyclosporine—Arrhythmia—Prednisone—systemic scleroderma	3e-05	0.000259	CcSEcCtD
Cyclosporine—SLCO1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.98e-05	0.00106	CbGpPWpGaD
Cyclosporine—Haematuria—Methotrexate—systemic scleroderma	2.98e-05	0.000257	CcSEcCtD
Cyclosporine—Vomiting—Leflunomide—systemic scleroderma	2.97e-05	0.000257	CcSEcCtD
Cyclosporine—PPIA—Hemostasis—NOS3—systemic scleroderma	2.97e-05	0.00105	CbGpPWpGaD
Cyclosporine—Alopecia—Prednisone—systemic scleroderma	2.97e-05	0.000256	CcSEcCtD
Cyclosporine—Hypersensitivity—Lisinopril—systemic scleroderma	2.96e-05	0.000256	CcSEcCtD
Cyclosporine—Hepatobiliary disease—Methotrexate—systemic scleroderma	2.95e-05	0.000255	CcSEcCtD
Cyclosporine—Dizziness—Mycophenolic acid—systemic scleroderma	2.95e-05	0.000255	CcSEcCtD
Cyclosporine—Epistaxis—Methotrexate—systemic scleroderma	2.95e-05	0.000255	CcSEcCtD
Cyclosporine—Rash—Leflunomide—systemic scleroderma	2.95e-05	0.000255	CcSEcCtD
Cyclosporine—Dermatitis—Leflunomide—systemic scleroderma	2.94e-05	0.000254	CcSEcCtD
Cyclosporine—Mental disorder—Prednisone—systemic scleroderma	2.94e-05	0.000254	CcSEcCtD
Cyclosporine—Nausea—Azathioprine—systemic scleroderma	2.94e-05	0.000254	CcSEcCtD
Cyclosporine—Headache—Leflunomide—systemic scleroderma	2.93e-05	0.000253	CcSEcCtD
Cyclosporine—Malnutrition—Prednisone—systemic scleroderma	2.92e-05	0.000253	CcSEcCtD
Cyclosporine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	2.9e-05	0.000251	CcSEcCtD
Cyclosporine—Asthenia—Lisinopril—systemic scleroderma	2.88e-05	0.000249	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	2.88e-05	0.000249	CcSEcCtD
Cyclosporine—Pruritus—Lisinopril—systemic scleroderma	2.84e-05	0.000246	CcSEcCtD
Cyclosporine—Vomiting—Mycophenolic acid—systemic scleroderma	2.83e-05	0.000245	CcSEcCtD
Cyclosporine—Haemoglobin—Methotrexate—systemic scleroderma	2.82e-05	0.000244	CcSEcCtD
Cyclosporine—Rash—Mycophenolic acid—systemic scleroderma	2.81e-05	0.000243	CcSEcCtD
Cyclosporine—Dermatitis—Mycophenolic acid—systemic scleroderma	2.81e-05	0.000243	CcSEcCtD
Cyclosporine—FKBP1A—Disease—HSPG2—systemic scleroderma	2.8e-05	0.000996	CbGpPWpGaD
Cyclosporine—Haemorrhage—Methotrexate—systemic scleroderma	2.8e-05	0.000242	CcSEcCtD
Cyclosporine—Hepatitis—Methotrexate—systemic scleroderma	2.8e-05	0.000242	CcSEcCtD
Cyclosporine—Urticaria—Mycophenolate mofetil—systemic scleroderma	2.79e-05	0.000242	CcSEcCtD
Cyclosporine—Headache—Mycophenolic acid—systemic scleroderma	2.79e-05	0.000241	CcSEcCtD
Cyclosporine—Pharyngitis—Methotrexate—systemic scleroderma	2.78e-05	0.000241	CcSEcCtD
Cyclosporine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	2.78e-05	0.00024	CcSEcCtD
Cyclosporine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	2.78e-05	0.00024	CcSEcCtD
Cyclosporine—Nausea—Leflunomide—systemic scleroderma	2.77e-05	0.00024	CcSEcCtD
Cyclosporine—Urinary tract disorder—Methotrexate—systemic scleroderma	2.77e-05	0.000239	CcSEcCtD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.75e-05	0.000978	CbGpPWpGaD
Cyclosporine—Vision blurred—Prednisone—systemic scleroderma	2.75e-05	0.000238	CcSEcCtD
Cyclosporine—Urethral disorder—Methotrexate—systemic scleroderma	2.75e-05	0.000238	CcSEcCtD
Cyclosporine—Diarrhoea—Lisinopril—systemic scleroderma	2.75e-05	0.000237	CcSEcCtD
Cyclosporine—Ill-defined disorder—Prednisone—systemic scleroderma	2.71e-05	0.000234	CcSEcCtD
Cyclosporine—FKBP1A—Disease—CSK—systemic scleroderma	2.71e-05	0.000962	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.71e-05	0.000961	CbGpPWpGaD
Cyclosporine—Visual impairment—Methotrexate—systemic scleroderma	2.7e-05	0.000234	CcSEcCtD
Cyclosporine—Anaemia—Prednisone—systemic scleroderma	2.7e-05	0.000233	CcSEcCtD
Cyclosporine—SLC10A1—Metabolism—HSPG2—systemic scleroderma	2.7e-05	0.000959	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—CTLA4—systemic scleroderma	2.7e-05	0.000957	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—SMAD7—systemic scleroderma	2.69e-05	0.000956	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—RHOB—systemic scleroderma	2.69e-05	0.000954	CbGpPWpGaD
Cyclosporine—Agitation—Prednisone—systemic scleroderma	2.68e-05	0.000232	CcSEcCtD
Cyclosporine—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.68e-05	0.000953	CbGpPWpGaD
Cyclosporine—Angioedema—Prednisone—systemic scleroderma	2.67e-05	0.000231	CcSEcCtD
Cyclosporine—Dizziness—Lisinopril—systemic scleroderma	2.65e-05	0.000229	CcSEcCtD
Cyclosporine—Nausea—Mycophenolic acid—systemic scleroderma	2.65e-05	0.000229	CcSEcCtD
Cyclosporine—Malaise—Prednisone—systemic scleroderma	2.63e-05	0.000228	CcSEcCtD
Cyclosporine—Vertigo—Prednisone—systemic scleroderma	2.62e-05	0.000227	CcSEcCtD
Cyclosporine—Tinnitus—Methotrexate—systemic scleroderma	2.61e-05	0.000226	CcSEcCtD
Cyclosporine—ABCC3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.6e-05	0.000922	CbGpPWpGaD
Cyclosporine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	2.59e-05	0.000224	CcSEcCtD
Cyclosporine—Vomiting—Lisinopril—systemic scleroderma	2.55e-05	0.000221	CcSEcCtD
Cyclosporine—SLCO1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.55e-05	0.000906	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—CD247—systemic scleroderma	2.55e-05	0.000904	CbGpPWpGaD
Cyclosporine—Angiopathy—Methotrexate—systemic scleroderma	2.54e-05	0.00022	CcSEcCtD
Cyclosporine—PPP3CA—Signaling Pathways—HSPG2—systemic scleroderma	2.53e-05	0.000899	CbGpPWpGaD
Cyclosporine—Rash—Lisinopril—systemic scleroderma	2.53e-05	0.000219	CcSEcCtD
Cyclosporine—Convulsion—Prednisone—systemic scleroderma	2.53e-05	0.000219	CcSEcCtD
Cyclosporine—Dermatitis—Lisinopril—systemic scleroderma	2.53e-05	0.000219	CcSEcCtD
Cyclosporine—Mediastinal disorder—Methotrexate—systemic scleroderma	2.53e-05	0.000218	CcSEcCtD
Cyclosporine—Asthenia—Mycophenolate mofetil—systemic scleroderma	2.52e-05	0.000218	CcSEcCtD
Cyclosporine—Hypertension—Prednisone—systemic scleroderma	2.52e-05	0.000218	CcSEcCtD
Cyclosporine—Chills—Methotrexate—systemic scleroderma	2.52e-05	0.000218	CcSEcCtD
Cyclosporine—Headache—Lisinopril—systemic scleroderma	2.51e-05	0.000217	CcSEcCtD
Cyclosporine—Pruritus—Mycophenolate mofetil—systemic scleroderma	2.49e-05	0.000215	CcSEcCtD
Cyclosporine—Arthralgia—Prednisone—systemic scleroderma	2.49e-05	0.000215	CcSEcCtD
Cyclosporine—Myalgia—Prednisone—systemic scleroderma	2.49e-05	0.000215	CcSEcCtD
Cyclosporine—Anxiety—Prednisone—systemic scleroderma	2.48e-05	0.000214	CcSEcCtD
Cyclosporine—Alopecia—Methotrexate—systemic scleroderma	2.48e-05	0.000214	CcSEcCtD
Cyclosporine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	2.47e-05	0.000214	CcSEcCtD
Cyclosporine—Discomfort—Prednisone—systemic scleroderma	2.46e-05	0.000212	CcSEcCtD
Cyclosporine—Mental disorder—Methotrexate—systemic scleroderma	2.46e-05	0.000212	CcSEcCtD
Cyclosporine—PPP3CA—Signaling Pathways—CSK—systemic scleroderma	2.45e-05	0.000869	CbGpPWpGaD
Cyclosporine—Malnutrition—Methotrexate—systemic scleroderma	2.44e-05	0.000211	CcSEcCtD
Cyclosporine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	2.41e-05	0.000208	CcSEcCtD
Cyclosporine—Dysgeusia—Methotrexate—systemic scleroderma	2.39e-05	0.000207	CcSEcCtD
Cyclosporine—Nausea—Lisinopril—systemic scleroderma	2.38e-05	0.000206	CcSEcCtD
Cyclosporine—Oedema—Prednisone—systemic scleroderma	2.38e-05	0.000206	CcSEcCtD
Cyclosporine—Anaphylactic shock—Prednisone—systemic scleroderma	2.38e-05	0.000206	CcSEcCtD
Cyclosporine—Infection—Prednisone—systemic scleroderma	2.37e-05	0.000205	CcSEcCtD
Cyclosporine—Nervous system disorder—Prednisone—systemic scleroderma	2.34e-05	0.000202	CcSEcCtD
Cyclosporine—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.33e-05	0.000201	CcSEcCtD
Cyclosporine—PPP3CA—Signaling by GPCR—EDN1—systemic scleroderma	2.32e-05	0.000824	CbGpPWpGaD
Cyclosporine—Skin disorder—Prednisone—systemic scleroderma	2.32e-05	0.0002	CcSEcCtD
Cyclosporine—Hyperhidrosis—Prednisone—systemic scleroderma	2.3e-05	0.000199	CcSEcCtD
Cyclosporine—Vision blurred—Methotrexate—systemic scleroderma	2.3e-05	0.000199	CcSEcCtD
Cyclosporine—Anorexia—Prednisone—systemic scleroderma	2.27e-05	0.000196	CcSEcCtD
Cyclosporine—Ill-defined disorder—Methotrexate—systemic scleroderma	2.27e-05	0.000196	CcSEcCtD
Cyclosporine—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.26e-05	0.000803	CbGpPWpGaD
Cyclosporine—Anaemia—Methotrexate—systemic scleroderma	2.26e-05	0.000195	CcSEcCtD
Cyclosporine—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.24e-05	0.000193	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—HLA-DQB1—systemic scleroderma	2.22e-05	0.000788	CbGpPWpGaD
Cyclosporine—ABCC3—NRF2 pathway—TGFB1—systemic scleroderma	2.22e-05	0.000788	CbGpPWpGaD
Cyclosporine—Rash—Mycophenolate mofetil—systemic scleroderma	2.22e-05	0.000192	CcSEcCtD
Cyclosporine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.22e-05	0.000192	CcSEcCtD
Cyclosporine—Headache—Mycophenolate mofetil—systemic scleroderma	2.2e-05	0.00019	CcSEcCtD
Cyclosporine—Malaise—Methotrexate—systemic scleroderma	2.2e-05	0.00019	CcSEcCtD
Cyclosporine—Vertigo—Methotrexate—systemic scleroderma	2.19e-05	0.00019	CcSEcCtD
Cyclosporine—Leukopenia—Methotrexate—systemic scleroderma	2.19e-05	0.000189	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.17e-05	0.000188	CcSEcCtD
Cyclosporine—Insomnia—Prednisone—systemic scleroderma	2.16e-05	0.000186	CcSEcCtD
Cyclosporine—Paraesthesia—Prednisone—systemic scleroderma	2.14e-05	0.000185	CcSEcCtD
Cyclosporine—Cough—Methotrexate—systemic scleroderma	2.13e-05	0.000184	CcSEcCtD
Cyclosporine—Convulsion—Methotrexate—systemic scleroderma	2.12e-05	0.000183	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—IL1A—systemic scleroderma	2.11e-05	0.000749	CbGpPWpGaD
Cyclosporine—Dyspepsia—Prednisone—systemic scleroderma	2.1e-05	0.000181	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—CD40LG—systemic scleroderma	2.1e-05	0.000744	CbGpPWpGaD
Cyclosporine—Nausea—Mycophenolate mofetil—systemic scleroderma	2.09e-05	0.000181	CcSEcCtD
Cyclosporine—FKBP1A—Signaling Pathways—RHOB—systemic scleroderma	2.08e-05	0.000739	CbGpPWpGaD
Cyclosporine—Myalgia—Methotrexate—systemic scleroderma	2.08e-05	0.00018	CcSEcCtD
Cyclosporine—Chest pain—Methotrexate—systemic scleroderma	2.08e-05	0.00018	CcSEcCtD
Cyclosporine—Arthralgia—Methotrexate—systemic scleroderma	2.08e-05	0.00018	CcSEcCtD
Cyclosporine—Decreased appetite—Prednisone—systemic scleroderma	2.07e-05	0.000179	CcSEcCtD
Cyclosporine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.06e-05	0.000178	CcSEcCtD
Cyclosporine—Fatigue—Prednisone—systemic scleroderma	2.06e-05	0.000178	CcSEcCtD
Cyclosporine—Discomfort—Methotrexate—systemic scleroderma	2.05e-05	0.000178	CcSEcCtD
Cyclosporine—SLC10A1—Metabolism—CTGF—systemic scleroderma	2.05e-05	0.000726	CbGpPWpGaD
Cyclosporine—Constipation—Prednisone—systemic scleroderma	2.04e-05	0.000176	CcSEcCtD
Cyclosporine—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.03e-05	0.000722	CbGpPWpGaD
Cyclosporine—Confusional state—Methotrexate—systemic scleroderma	2.01e-05	0.000174	CcSEcCtD
Cyclosporine—Anaphylactic shock—Methotrexate—systemic scleroderma	1.99e-05	0.000172	CcSEcCtD
Cyclosporine—Infection—Methotrexate—systemic scleroderma	1.98e-05	0.000171	CcSEcCtD
Cyclosporine—Feeling abnormal—Prednisone—systemic scleroderma	1.96e-05	0.00017	CcSEcCtD
Cyclosporine—FKBP1A—Signaling Pathways—HSPG2—systemic scleroderma	1.96e-05	0.000697	CbGpPWpGaD
Cyclosporine—PPIA—Hemostasis—TGFB1—systemic scleroderma	1.96e-05	0.000696	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—SMAD7—systemic scleroderma	1.96e-05	0.000695	CbGpPWpGaD
Cyclosporine—Nervous system disorder—Methotrexate—systemic scleroderma	1.95e-05	0.000169	CcSEcCtD
Cyclosporine—Thrombocytopenia—Methotrexate—systemic scleroderma	1.95e-05	0.000169	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Prednisone—systemic scleroderma	1.95e-05	0.000169	CcSEcCtD
Cyclosporine—Skin disorder—Methotrexate—systemic scleroderma	1.94e-05	0.000167	CcSEcCtD
Cyclosporine—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.93e-05	0.000686	CbGpPWpGaD
Cyclosporine—Hyperhidrosis—Methotrexate—systemic scleroderma	1.93e-05	0.000167	CcSEcCtD
Cyclosporine—Anorexia—Methotrexate—systemic scleroderma	1.9e-05	0.000164	CcSEcCtD
Cyclosporine—FKBP1A—Signaling Pathways—CSK—systemic scleroderma	1.9e-05	0.000673	CbGpPWpGaD
Cyclosporine—Urticaria—Prednisone—systemic scleroderma	1.89e-05	0.000164	CcSEcCtD
Cyclosporine—Body temperature increased—Prednisone—systemic scleroderma	1.88e-05	0.000163	CcSEcCtD
Cyclosporine—Abdominal pain—Prednisone—systemic scleroderma	1.88e-05	0.000163	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	1.82e-05	0.000157	CcSEcCtD
Cyclosporine—Insomnia—Methotrexate—systemic scleroderma	1.8e-05	0.000156	CcSEcCtD
Cyclosporine—ABCC1—Disease—TGFBI—systemic scleroderma	1.79e-05	0.000635	CbGpPWpGaD
Cyclosporine—Paraesthesia—Methotrexate—systemic scleroderma	1.79e-05	0.000155	CcSEcCtD
Cyclosporine—Dyspnoea—Methotrexate—systemic scleroderma	1.78e-05	0.000154	CcSEcCtD
Cyclosporine—Somnolence—Methotrexate—systemic scleroderma	1.77e-05	0.000153	CcSEcCtD
Cyclosporine—ABCC2—NRF2 pathway—TGFB1—systemic scleroderma	1.76e-05	0.000625	CbGpPWpGaD
Cyclosporine—Hypersensitivity—Prednisone—systemic scleroderma	1.76e-05	0.000152	CcSEcCtD
Cyclosporine—Dyspepsia—Methotrexate—systemic scleroderma	1.75e-05	0.000152	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	1.74e-05	0.000618	CbGpPWpGaD
Cyclosporine—Decreased appetite—Methotrexate—systemic scleroderma	1.73e-05	0.00015	CcSEcCtD
Cyclosporine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	1.72e-05	0.000149	CcSEcCtD
Cyclosporine—Fatigue—Methotrexate—systemic scleroderma	1.72e-05	0.000149	CcSEcCtD
Cyclosporine—Asthenia—Prednisone—systemic scleroderma	1.71e-05	0.000148	CcSEcCtD
Cyclosporine—Pain—Methotrexate—systemic scleroderma	1.7e-05	0.000147	CcSEcCtD
Cyclosporine—Pruritus—Prednisone—systemic scleroderma	1.69e-05	0.000146	CcSEcCtD
Cyclosporine—Feeling abnormal—Methotrexate—systemic scleroderma	1.64e-05	0.000142	CcSEcCtD
Cyclosporine—Diarrhoea—Prednisone—systemic scleroderma	1.63e-05	0.000141	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Methotrexate—systemic scleroderma	1.63e-05	0.000141	CcSEcCtD
Cyclosporine—ABCB11—Metabolism—HSPG2—systemic scleroderma	1.59e-05	0.000565	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling by GPCR—CCL2—systemic scleroderma	1.59e-05	0.000563	CbGpPWpGaD
Cyclosporine—Urticaria—Methotrexate—systemic scleroderma	1.58e-05	0.000137	CcSEcCtD
Cyclosporine—Dizziness—Prednisone—systemic scleroderma	1.58e-05	0.000136	CcSEcCtD
Cyclosporine—Abdominal pain—Methotrexate—systemic scleroderma	1.58e-05	0.000136	CcSEcCtD
Cyclosporine—Body temperature increased—Methotrexate—systemic scleroderma	1.58e-05	0.000136	CcSEcCtD
Cyclosporine—ABCC3—Metabolism—HSPG2—systemic scleroderma	1.53e-05	0.000542	CbGpPWpGaD
Cyclosporine—Vomiting—Prednisone—systemic scleroderma	1.52e-05	0.000131	CcSEcCtD
Cyclosporine—Rash—Prednisone—systemic scleroderma	1.5e-05	0.00013	CcSEcCtD
Cyclosporine—Dermatitis—Prednisone—systemic scleroderma	1.5e-05	0.00013	CcSEcCtD
Cyclosporine—Headache—Prednisone—systemic scleroderma	1.49e-05	0.000129	CcSEcCtD
Cyclosporine—Hypersensitivity—Methotrexate—systemic scleroderma	1.47e-05	0.000127	CcSEcCtD
Cyclosporine—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.47e-05	0.00052	CbGpPWpGaD
Cyclosporine—PPIA—Disease—NOS3—systemic scleroderma	1.44e-05	0.00051	CbGpPWpGaD
Cyclosporine—Asthenia—Methotrexate—systemic scleroderma	1.43e-05	0.000124	CcSEcCtD
Cyclosporine—ABCC1—Disease—HSPG2—systemic scleroderma	1.43e-05	0.000507	CbGpPWpGaD
Cyclosporine—Nausea—Prednisone—systemic scleroderma	1.42e-05	0.000122	CcSEcCtD
Cyclosporine—Pruritus—Methotrexate—systemic scleroderma	1.41e-05	0.000122	CcSEcCtD
Cyclosporine—SLC10A2—Metabolism—NOS3—systemic scleroderma	1.38e-05	0.000491	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—CSK—systemic scleroderma	1.38e-05	0.000489	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—EDN1—systemic scleroderma	1.37e-05	0.000487	CbGpPWpGaD
Cyclosporine—Diarrhoea—Methotrexate—systemic scleroderma	1.36e-05	0.000118	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	1.35e-05	0.00048	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—HSPG2—systemic scleroderma	1.33e-05	0.000472	CbGpPWpGaD
Cyclosporine—Dizziness—Methotrexate—systemic scleroderma	1.32e-05	0.000114	CcSEcCtD
Cyclosporine—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.31e-05	0.000465	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—CD247—systemic scleroderma	1.3e-05	0.00046	CbGpPWpGaD
Cyclosporine—Vomiting—Methotrexate—systemic scleroderma	1.27e-05	0.00011	CcSEcCtD
Cyclosporine—Rash—Methotrexate—systemic scleroderma	1.26e-05	0.000109	CcSEcCtD
Cyclosporine—Dermatitis—Methotrexate—systemic scleroderma	1.26e-05	0.000109	CcSEcCtD
Cyclosporine—Headache—Methotrexate—systemic scleroderma	1.25e-05	0.000108	CcSEcCtD
Cyclosporine—ABCB11—Metabolism—CTGF—systemic scleroderma	1.21e-05	0.000428	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—HSPG2—systemic scleroderma	1.2e-05	0.000424	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—NOS3—systemic scleroderma	1.19e-05	0.000424	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.19e-05	0.000424	CbGpPWpGaD
Cyclosporine—Nausea—Methotrexate—systemic scleroderma	1.18e-05	0.000102	CcSEcCtD
Cyclosporine—ABCC3—Metabolism—CTGF—systemic scleroderma	1.16e-05	0.000411	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	1.14e-05	0.000403	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.11e-05	0.000394	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—IL1B—systemic scleroderma	1.1e-05	0.00039	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—EDN1—systemic scleroderma	1.06e-05	0.000378	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—HSPG2—systemic scleroderma	1.05e-05	0.000373	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—HSPG2—systemic scleroderma	1.04e-05	0.00037	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—CTGF—systemic scleroderma	1.01e-05	0.000357	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.91e-06	0.000352	CbGpPWpGaD
Cyclosporine—PPIA—Disease—TGFB1—systemic scleroderma	9.49e-06	0.000337	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—CCL2—systemic scleroderma	9.37e-06	0.000333	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—NOS3—systemic scleroderma	9.25e-06	0.000328	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—CTGF—systemic scleroderma	9.06e-06	0.000322	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.04e-06	0.000321	CbGpPWpGaD
Cyclosporine—SLC10A1—Metabolism—NOS3—systemic scleroderma	8.91e-06	0.000316	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism—CTGF—systemic scleroderma	8.61e-06	0.000306	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—NOS3—systemic scleroderma	8.36e-06	0.000297	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—CTGF—systemic scleroderma	7.97e-06	0.000283	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—CTGF—systemic scleroderma	7.9e-06	0.000281	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—TGFB1—systemic scleroderma	7.89e-06	0.00028	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—HSPG2—systemic scleroderma	7.54e-06	0.000268	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—CCL2—systemic scleroderma	7.27e-06	0.000258	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—MMP9—systemic scleroderma	6.7e-06	0.000238	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.67e-06	0.000237	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—HSPG2—systemic scleroderma	6.53e-06	0.000232	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—NOS3—systemic scleroderma	6.48e-06	0.00023	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—TGFB1—systemic scleroderma	6.12e-06	0.000217	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—HSPG2—systemic scleroderma	5.83e-06	0.000207	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—CTGF—systemic scleroderma	5.71e-06	0.000203	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—HSPG2—systemic scleroderma	5.69e-06	0.000202	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—TGFB1—systemic scleroderma	5.52e-06	0.000196	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—HSPG2—systemic scleroderma	5.36e-06	0.00019	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—HSPG2—systemic scleroderma	5.31e-06	0.000189	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism—NOS3—systemic scleroderma	5.25e-06	0.000186	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—MMP9—systemic scleroderma	5.2e-06	0.000185	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism—NOS3—systemic scleroderma	5.03e-06	0.000179	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—CTGF—systemic scleroderma	4.95e-06	0.000176	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—NOS3—systemic scleroderma	4.71e-06	0.000167	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—CTGF—systemic scleroderma	4.42e-06	0.000157	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—NOS3—systemic scleroderma	4.38e-06	0.000156	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—CTGF—systemic scleroderma	4.31e-06	0.000153	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—TGFB1—systemic scleroderma	4.28e-06	0.000152	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—CTGF—systemic scleroderma	4.06e-06	0.000144	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—CTGF—systemic scleroderma	4.03e-06	0.000143	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—NOS3—systemic scleroderma	3.94e-06	0.00014	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism—NOS3—systemic scleroderma	3.75e-06	0.000133	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.5e-06	0.000124	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—NOS3—systemic scleroderma	3.47e-06	0.000123	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—NOS3—systemic scleroderma	3.44e-06	0.000122	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—TGFB1—systemic scleroderma	3.11e-06	0.000111	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.66e-06	9.43e-05	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—NOS3—systemic scleroderma	2.49e-06	8.83e-05	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—NOS3—systemic scleroderma	2.15e-06	7.65e-05	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—NOS3—systemic scleroderma	1.92e-06	6.82e-05	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—NOS3—systemic scleroderma	1.88e-06	6.66e-05	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—NOS3—systemic scleroderma	1.77e-06	6.28e-05	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.75e-06	6.22e-05	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.16e-06	4.1e-05	CbGpPWpGaD
